Home › Listed IPOs › Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPOLISTED
Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in manufacturing APIs, nutritional ingredients, and specialty products.
Listing price
₹988
Listing gain
+0.00%
Current
₹988
Listed
01 Sept 26
Opens
24 Aug 26Closes
27 Aug 26Allotment
28 Aug 26Refund
31 Aug 26Demat
31 Aug 26Listing
01 Sept 26Listed at
₹988
+0.00% on 01 Sept 26
Overview
Price band
₹938-988
Lot size
15 shares
Min. investment
₹14,820
Issue size
₹1757.00 Cr
1.78 Cr shares
Fresh issue
₹150 Cr
15.21 L shares
Offer for sale
₹1,607 Cr
1.63 Cr shares
Face value
₹2 / share
Issue type
Book Built Issue
Listing at
NSE, BSE
Employee discount
₹90
Reservation
| Category | Shares offered | % of issue |
|---|---|---|
| Anchor Investor | 53,25,909 | 29.94% |
| QIB | 35,50,608 | 19.96% |
| NII (HNI) | 26,62,955 | 14.97% |
| B-HNI | 17,75,303 | 9.98% |
| S-HNI | 8,87,652 | 4.99% |
| Individual | 62,13,562 | 34.93% |
| Employee | 33,408 | 0.19% |
| Total | 1,77,86,442 | 99.99% |
Lot size & investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Listing performance
NSE/BSE: SYMBIOTECListing gain
0.00%
Gain per retail lot
₹0
Latest vs issue
—
GMP was
₹240 (+24.29%)
Issue price
GMP estimate
Listing price
Latest price appears here during market hours.
Symbiotec Pharmalab Live GMP
Latest GMP
₹240
All-time high
₹340
All-time low
₹220
Subscription
28 Aug, 12:00 amOversubscribed 75.06 times · 52,87,461 applications
Total applications
52,87,461
Total bid amount
₹92,403 Cr
Category breakdown
| Category | Shares offered | Shares bid | Times | Bid amount |
|---|---|---|---|---|
| QIB | 35,50,608 | 64,33,59,195 | 181.20x | ₹63,564 Cr |
| NII (HNI) | 26,62,955 | 20,65,35,120 | 77.56x | ₹20,406 Cr |
| B-HNI | 17,75,303 | 15,50,46,495 | 87.34x | ₹15,319 Cr |
| S-HNI | 8,87,652 | 5,14,88,625 | 58.01x | ₹5,087 Cr |
| Retail | 62,13,562 | 8,48,10,750 | 13.65x | ₹8,379 Cr |
| Employee | 33,408 | 5,45,055 | 16.32x | ₹53.85 Cr |
| Total | 1,24,60,533 | 93,52,50,120 | 75.06x | ₹92,403 Cr |
Application-wise breakup
| Category | Applications reserved | Applied | Times |
|---|---|---|---|
| B-HNI | 8,454 | 1,50,254 | 17.77x |
| S-HNI | 4,227 | 2,37,513 | 56.19x |
| Retail | 4,14,238 | 48,46,627 | 11.70x |
| Employee | 0 | 23,445 | — |
Allotment chance per application is roughly 1 ÷ times for the category (lottery for retail and S-HNI).
Financials
(₹ in crores)
Key performance indicators
As of 31 Mar 2026ROE
11.19%
PAT Margin
12.6%
ROCE
11.56%
EBITDA Margin
26.59%
Price to Book Value
5.35
RoNW
9.48%
Valuation vs listed peers
EPS Pre IPO
₹17.82
EPS Post IPO
₹17.39
P/E Pre IPO
55.44
P/E Post IPO
56.81
Price-to-earnings
| Company | P/E | P/B | RoNW | Face value |
|---|---|---|---|---|
| Concord Biotech Limited | 61.07 | — | — | — |
| Divi’s Laboratories Limited | 87.8 | — | — | — |
| Cohance Lifesciences Limited | 95.02 | — | — | — |
| Laurus Labs Limited | 109.36 | — | — | — |
Peer median P/E 91.4× · Ratios as disclosed in the offer document.
Buzz AI analysis
From this IPO's filings and market data · educational, not investment advice
Revenue growth FY24 → FY26
+20.6%
Profit growth FY24 → FY26
+9.8%
P/E vs peer median
56.8× vs 91.4×
- PAT margin 12.6% and ROCE 11.6%.
- Priced below its listed-peer median P/E.
Strengths & risks
- Strong 60+ API portfolio across key therapeutic segments.
- Serves 200+ customers across 40+ countries.
- Backward-integrated manufacturing with global regulatory approvals.
- Expanding into CDMO services and complex injectables.
- Strong financial growth with improving profitability.
Buzz score · Neutral
From GMP, subscription and issue size
Objects of the issue
| Purpose | Amount (₹ Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company. | 112.5 |
| General corporate purposes. | - |
Company & documents
Symbiotec Pharmalab Ltd. is a research-driven pharmaceutical and biotechnology company focused on APIs, corticosteroid and steroidal-hormone products, CDMO services, and complex injectables.
With over 30 years of experience, Symbiotec has evolved into a backward-integrated pharmaceutical platform with capabilities in fermentation, biosynthesis, biotransformation, and chemical synthesis, supported by global regulatory approvals.
The company has a portfolio of 60+ corticosteroid and steroidal-hormone APIs, including Hydrocortisone, Betamethasone, Methylprednisolone, Progesterone, Estrogen, and Testosterone, supplied to global markets.
Symbiotec operates across three business verticals: API Products, CDMO Services, and Complex Injectables, including double-chamber injectable technologies.
The company follows a “farm/microbe-to-pharmacy” model, using fermentation and in-house manufacturing of key starting materials to reduce dependence on external suppliers.
As of March 31, 2026, Symbiotec had manufacturing facilities in Rau, Pithampur, Ujjain and Mhow, with 584.67 MT chemical synthesis and 700 KL fermentation capacity, plus capacity for 20 million complex injectable vials annually.
Symbiotec serves 200+ customers across 40+ countries, with international markets contributing 67.04% of revenue from operations in Fiscal 2026.
Registrar
MUFG Intime India Pvt. Ltd.
Phone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Web: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Company contact
Symbiotec Pharmalab Ltd.
385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Book running lead managers
- JM Financial Limited
- Avendus Capital Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
Promoters
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP.